MGNX · NASDAQ
MacroGenics, Inc.
$2.26 +0.01 (+0.44%)
Company overview
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC) targeting solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody targeting B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule designed to minimize cytokine-release syndrome for patients with hematologic malignancies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $144M
- Employees
- 341
- Headquarters
- Rockville, MD
- Website
- macrogenics.com
- CEO
- Eric Blasius Risser
- Listed
- October 10, 2013
- P/E
- -2.05
- Dividend yield
- 0.00%
Company financials
- Revenue
- $157M
- Gross profit
- $110M
- Operating income
- -$63.7M
- EBITDA
- -$56.6M
- Net income
- -$70.4M
- EPS
- -$1.10
- Total assets
- $218M
- Total debt
- $36.5M
- Gross margin
- 69.93%
- Net margin
- -44.79%
- Earnings yield
- -48.67%
No geographic segmentation.
Showing FY 2025
MGNX
1D
NASDAQ
O3.55H3.57L2.13C2.25-1.38 (-38.02%)Vol4.01M